

Neuropathy patients more likely to receive high-cost, screening instead of more effective tests

January 23 2012

Researchers at the University of Michigan analyzed the tremendous cost of diagnosing peripheral neuropathy and found that less expensive, more effective tests are less likely to be used.

Almost one-quarter of patients receiving neuropathy diagnoses undergo high-cost, low-yield MRIs while very few receive low-cost, high-yield glucose tolerance tests, according to the study that will be published Jan. 23 in the [Archives of Internal Medicine](#).

The research was led by Brian Callaghan, M.D., assistant professor of [neurology](#) at the University of Michigan Medical School.

Patients diagnosed with [peripheral neuropathy](#) typically are given many tests but physicians are highly variable in their approach, says Callaghan.

"We spend a lot of money to work up a diagnosis of neuropathy. The question is whether that money is well spent," Callaghan says.

For patients with peripheral neuropathy, the nerves that carry information to and from the [brain](#) don't work properly. This commonly leads to tingling or burning in arms or [legs](#) and loss of feeling — and the symptoms can go from subtle to severe.

Diabetes is the most common cause of this type of [nerve](#) problem.

Peripheral neuropathy is found in about 15 percent of those over age 40.

Researchers used the 1996-2007 Health and Retirement Study to identify individuals with a diagnosis of peripheral neuropathy. They focused on 15 relevant tests and examined the number and patterns of tests six months before and after the initial diagnosis.

"Our findings, that MRIs were frequently ordered by [physicians](#), but a lower-cost glucose tolerance test was rarely ordered, show that there is substantial opportunity to improve efficiency in the evaluation of peripheral neuropathy," Callaghan says.

"Currently no standard approach to the evaluation of peripheral neuropathy exists. We need more research to determine an optimal approach.

"We do a lot of tests that cost a lot of money, and there's no agreement on what we're doing."

The climbing rates of diabetes in the U.S. make this research even more important, says co-author Kenneth M. Langa, M.D., Ph.D., a professor of Internal Medicine at U-M, a Research Scientist at the VA Ann Arbor Healthcare System's Center for Clinical Management Research, and Research Professor at the Institute for Social Research.

"We know more and more people may develop peripheral neuropathy because it is commonly caused by diabetes. Our study suggests that the work-up currently used for neuropathy isn't standardized and tests that are less useful and more expensive may be used too often," says Langa. "We need a more efficient way to handle this increasingly common [diagnosis](#)."

More information: *Arch Intern Med.* 2012; 172[2]:127-132.

Provided by University of Michigan

Citation: Neuropathy patients more likely to receive high-cost, screening instead of more effective tests (2012, January 23) retrieved 13 March 2024 from <https://medicalxpress.com/news/2012-01-neuropathy-patients-high-cost-screening-effective.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.